Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that activate the immune system, aiming at enhancing antitumor immunity. Their clinical efficacy is well-documented, but the side effects associated with their use are still under investigation. These drugs cause several immune-related ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Melissaropoulos, Konstantinos, Klavdianou, Kalliopi, Filippopoulou, Alexandra, Kalofonou, Fotini, Kalofonos, Haralabos, Daoussis, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247001/
https://www.ncbi.nlm.nih.gov/pubmed/32403289
http://dx.doi.org/10.3390/ijms21093389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247001/
https://www.ncbi.nlm.nih.gov/pubmed/32403289
http://dx.doi.org/10.3390/ijms21093389

Ejemplares similares